Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We evaluated expression of Sox10 and DOG1 in normal cutaneous adnexa and in 194 primary skin adnexal tumors, and compared their performance in discriminating primary skin adnexal tumors from cutaneous metastatic adenocarcinomas with that of p40 and p63.
|
28394798 |
2017 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Diagnostic combinations were p40-/TTF1+ or TTF1- for AD (where p40 was negative, apart from 5/30 AD showing at the best 1-2% tumor cells with low intensity); p40+/TTF1- (p40 strong and by far higher than 50%) for SQC; and p40+/TTF1+ or p40+/TTF1- (p40 strong and less than 50%) for ADSQC.
|
22071786 |
2012 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We characterized captured cells using TTF1 and p40 as immunostaining biomarkers of adenocarcinoma and squamous cell carcinoma, respectively.
|
28298147 |
2017 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Cell differentiation lineages were unveiled by using thyroid transcription factor-1 (TTF1) for adenocarcinoma (ADC) and p40 for squamous cell carcinoma (SQC), dichotomizing immunohistochemistry (IHC) results for TTF1 as negative or positive (whatever its extent) and for p40 as negative, positive, or focal (if <10% of reactive tumor cells).
|
26317919 |
2015 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Polyclonal p40 yields a level of false positivity in ACAs similar to p63, which is highest in effusions and is not limited to lung origin.
|
28498881 |
2017 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
TTF-1 and napsin A IHC stainings had similar specificity but better sensitivity for adenocarcinoma than the mucin stains, but addition of PASD or ABPAS identified more tumors as adenocarcinomas (n = 8 and n = 10, respectively) than napsin A (n = 1) in cases with solid growth that were negative for TTF-1 and p40.
|
30718697 |
2019 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Utility of p63 and p40 in Distinguishing Polymorphous Adenocarcinoma and Adenoid Cystic Carcinoma.
|
31653135 |
2019 |
Adenocarcinoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Confirmatory fluorescence in-situ hybridization (FISH) using a break-apart probe to the TP63 gene region and immunohistochemistry for p63 and p40 were performed on adenocarcinomas with TP63 rearrangements identified by mate-pair sequencing.
|
25189640 |
2015 |
Adenocarcinoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Spatial proximity between bronchus and ALK-rearranged tumors and frequent solid histologic subtype with p63 expression may cause diagnostic difficulties to differentiate squamous cell carcinoma in the small biopsy, whereas p40 was rarely expressed in ALK-rearranged adenocarcinoma.
|
24194854 |
2013 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As tumor cells showed positive immunostaining for p40 and CK5/6, the immunophenotype of the tumor was consistent with squamous cell carcinoma (SCC).
|
30216599 |
2018 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although P40 staining for the sarcomatous component was positive along with squamous carcinoma, E-cadherin expression disappeared while vimentin was expressed.
|
31366562 |
2019 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IHC marker p40 (ΔNp63) is a truncated isoform of p63 that is a promising IHC marker for SQCC.
|
24166777 |
2014 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Both lesions were squamous cell carcinoma and positive for p40.
|
31845086 |
2019 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Once a broad tumor class is established, more specific differentiation markers can be pursued (e.g., lineage-restricted transcription factors for adenocarcinoma; p40 for squamous cell carcinoma; chromogranin A and synaptophysin or INSM1 for neuroendocrine neoplasms).
|
31786484 |
2020 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokeratin 5/6 (CK5/6), p63, and p40 are commonly used as immunohistochemical markers for squamous cell carcinoma (SqCC) of the lung.
|
30546464 |
2018 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We characterized captured cells using TTF1 and p40 as immunostaining biomarkers of adenocarcinoma and squamous cell carcinoma, respectively.
|
28298147 |
2017 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Negativity or focal occurrence of p40 made SQC diagnosis unlikely on molecular grounds, but suggested ADC confirming validity of the axiom "no p40, no squamous."
|
26317919 |
2015 |
Squamous cell carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Spatial proximity between bronchus and ALK-rearranged tumors and frequent solid histologic subtype with p63 expression may cause diagnostic difficulties to differentiate squamous cell carcinoma in the small biopsy, whereas p40 was rarely expressed in ALK-rearranged adenocarcinoma.
|
24194854 |
2013 |
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diagnostic combinations were p40-/TTF1+ or TTF1- for AD (where p40 was negative, apart from 5/30 AD showing at the best 1-2% tumor cells with low intensity); p40+/TTF1- (p40 strong and by far higher than 50%) for SQC; and p40+/TTF1+ or p40+/TTF1- (p40 strong and less than 50%) for ADSQC.
|
22071786 |
2012 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notably, the recently described IL-23 shares the p40 subunit with IL-12, raising the possibility that the clinical benefit of the anti-IL-12/p40 antibody in CD may also be due to the neutralization of IL-23 activity.
|
17007011 |
2006 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-12 p35 and p40 antisense probes were used to examine ileal specimens from 9 children with CD and gastric biopsies from 24 children (13 with CD, 6 with Helicobacter pylori chronic gastritis, and 5 with a normal gastric mucosa).
|
9502407 |
1998 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lastly, ustekinumab, a monoclonal antibody (mAb) to the p40 subunit of IL-12 and IL-23, has showed good efficacy and safety profile in patients with Crohn's disease (CD).
|
30060945 |
2018 |
Crohn Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Ustekinumab is a monoclonal antibody that binds with high affinity to the p40 subunit of human interleukin 12 (IL12 and IL23) that has been approved for treatment of patients with moderate to severe Crohn's disease (CD).
|
29409871 |
2018 |
Crohn Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Polymorphisms within the genes encoding the IL-12 p40 subunit, IL12B, and one of the IL-23 receptor subunits, IL23R, have been replicated in US and European populations and overlap with risk of Crohn's disease.
|
18830267 |
2009 |